Answers are grounded in this paper and cite their sources.
Squamous cell carcinoma of the head and neck (SCCHN) is comprised of two distinct entities: tobacco-associated, human papil-lomavirus (HPV) –negative SCCHN, and HPV-positive SCCHN.1,2 HPV-positive tumors arise primarily in the oropharynx and have a favorable prognosis when treated with chemotherapy, radiation, sur-gery, or chemoradiotherapy.3-8 p16 immunohistochemistry (IHC), which is widely used as a surrogate marker of HPV, and direct detec-tion of HPV genetic material (eg, using in situ hybridization [ISH] or polymerase chain reaction [PCR]) are powerful, well-established prognostic biomarkers for oropharyngeal (OP) SCCHN. HPV-positive SCCHN shows absence of alterations of the tumor suppres-sors TP53 and CDKN2A because p53 and p16 proteins are already inactivated by HPV E6/E7 viral proteins. Genetically, HPV-positive SCCHN tumors closely resemble cervical cancers.1,2 By contrast, HPV-negative tumors arise throughout the upper aerodigestive tract
No takes yet. Share an insight, caveat, or question.
Tanguy Y. Seiwert (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: